Prostate Cancer Treatment Algorithm

EP. 1: Prostate Cancer in 2025

ByRohit Gosain, MD,Rahul Gosain, MD,Alan H. Bryce, MD

March 24th 2025

Experts give an overview of the treatment landscape in prostate cancer as of 2025.

EP. 2: Consideration for Other Androgen Receptor Inhibitors

ByRohit Gosain, MD,Rahul Gosain, MD,Alan H. Bryce, MD

March 24th 2025

Experts discuss considerations for other androgen receptor inhibitors, highlighting their role in treatment strategies and how they impact patient outcomes in prostate cancer.

EP. 3: Making Sense of PARP Inhibitors

ByRohit Gosain, MD,Rahul Gosain, MD,Alan H. Bryce, MD

March 24th 2025

Experts discuss the role of PARP inhibitors in prostate cancer treatment, exploring their mechanisms, clinical benefits, and how they fit into current therapeutic strategies.

EP. 4: Deciding Which RP to Utilize

ByRohit Gosain, MD,Rahul Gosain, MD,Alan H. Bryce, MD

March 24th 2025

Experts discuss how to decide which robotic prostatectomy (RP) approach to utilize, considering factors such as patient characteristics, surgical outcomes, and the latest clinical evidence.

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC

TIP127 TroFuse-012: A Phase 3, Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab Vs Treatment of Physician’s Choice in Participants With Triple-Negative Breast Cancer who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery